4:00 AM
 | 
Apr 04, 2018
 |  BC Extra  |  Company News

Sigilon finds partner in Lilly for T1D encapsulated cell therapy

Sigilon Therapeutics Inc. (Cambridge, Mass.) granted Eli Lilly and Co. (NYSE:LLY) exclusive, worldwide rights to Sigilon's Type I diabetes program in a deal potentially worth over $470 million.

Lilly will pay Sigilon $63 million up front and up to $410 million in development and commercial milestones. The pharma will also make an undisclosed investment in...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >